InspireMD

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InspireMD reports strong Q1 performance, eyes future growth opportunities

InspireMD's Q1 2024 showcased revenue growth and promising trial results, but challenges in gross profit and rising expenses. Strategic agreements and upcoming product approvals present opportunities for future growth and innovation.

InspireMD reports revenue growth, faces cost challenges, eyes U.S. launch

InspireMD's Q2 2024 performance reflects revenue growth but challenges in managing costs and achieving profitability.
The company's strengths lie in groundbreaking clinical outcomes, successful financings, and preparations for a U.S. commercial launch.
While facing cost and financial challenges, InspireMD has opportunities to drive market expansion, innovation, and capitalize on its strong cash position.
Balancing growth initiatives with cost control will be key for InspireMD's sustainable financial success and market competitiveness.

InspireMD reports 16% revenue growth in Q3 2024 earnings call

InspireMD's Q3 performance reflects revenue growth but challenges in profitability due to cost dynamics.
The company's strategic strengths lie in international sales, product innovation, and U.S. market focus.
Opportunities include FDA approvals, market expansion, and strong financial position for growth initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

- Biennial Scientific Meeting of the IAGS to be held from January 31st – February 3rd 2022 - - Biennial Scientific Meeting of the IAGS to be held from January 31st – February 3rd 2022 -

InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)

It's been a shaky start to the year for markets as a hawkish Fed, and the prospect of rising rates has many advisors looking further afield for income opportunities. Strategies that have carried retirement portfolios on an economy of largely solid growth for the last decade or two are now being put to the test [.

Seeking Income in Challenging Times for Retirement Portfolios

Live Case will be Broadcasted Today at 11:00am ET Live Case will be Broadcasted Today at 11:00am ET

InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial

InspireMD, Inc. (NSPAR) CEO Marvin Slosman on Q3 2021 Results - Earnings Call Transcript

-CGuard™ sales generated 24% YoY revenue growth-

InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET

InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update

Denison Mines

NeuroBo Pharmaceuticals Inc

Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? Here's 3 For Your Watchlist in October

The stock price of InspireMD Inc (NASDAQ: NSPR) increased by over 5% today. This is why it happened.

NSPR Stock: Why It Increased Today

TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS) regarding reimbursement in France, and the CGuard EPS is being added to the list of reimbursed medical products (LPPR) effective October 25, 2021. This was the final step to full commercial launch of CGuard EPS following CNEDIMTS' positive opinion for reimbursement received by the Company on May 11, 2021 for the treatment of symptomatic and non-symptomatic lesions when surgery is not indicated.

InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health

Qudian

There are some investors who purchase U.S.-listed stocks that are trading below their liquidation values because they believe they can get a huge return out of these stocks after the market has reappraised the share prices to near or above the liquidation value.

2 Net Current Asset Value Stock Picks to Consider

InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q2 2021 Results - Earnings Call Transcript

Revenue rebound, strong procedural recovery

InspireMD Announces Strong Second Quarter 2021 Financial Results

TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the Company's U.S. registration C-Guardian trial of CGuard EPS.

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.

InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

Ticker to remain NSPR Ticker to remain NSPR

InspireMD Commences Trading on Nasdaq-CM

TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.

InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021

TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appointed seasoned marketing executive Kathryn (Katie) Arnold to its Board of Directors. With more than two decades of strategy and commercialization experience within the medical device industry, Ms. Arnold joins as the company advances global commercialization and enrollment in the U.S. IDE trial of its novel CGuard EPS technology.

InspireMD Announces Appointment of Katie Arnold to Board of Directors

InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2021 Results - Earnings Call Transcript

Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021

InspireMD Announces First Quarter 2021 Financial Results

InspireMD Announces Stock Exchange Listing Transfer to Nasdaq

TEL AVIV, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announces the formation of its Scientific Advisory Board with its newly appointed chair, acclaimed interventional cardiologist, Kenneth Rosenfield, M.D.

InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.

PreMarket Prep Stock Of The Day: InspireMD

InspireMD has vastly reduced the number of its shares trading ahead of a likely move to a Nasdaq listed. Conversion of NSPR stock warrants and preferred shares will be more difficult now.

NSPR Stock: What You Should Know About InspireMD Today

InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB) recently announced a 1-for-15 reverse split of its common stock, effective as of yesterday. These are the details.

NSPR Stock: 1-For-15 Reverse Stock Split

TEL AVIV, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today provided an update of recent corporate developments.

News for InspireMD Stock (NSPR)